Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for roughly 3% of all cancer diagnoses, with a notably higher occurrence in Western countries, likely linked to the increased detection of small renal masses. Despite advancements in targeted therapies and immunotherapies, the prognosis for stage IV RCC remains challenging, with a 5-year survival rate of only 17%. Furthermore, non-clear cell RCC, which constitutes about 20-25% of RCC cases, continues to present a significant unmet need in terms of treatment options.
Our infographic provides a succinct overview of the current treatment landscape for RCC, spotlighting both established and novel therapeutic approaches. It underscores the critical need for continued research and development to improve outcomes for all RCC patients, particularly those with non-clear cell histologies. Join us in recognizing March as Kidney Cancer Awareness Month by exploring the evolving strategies in the fight against this disease.
Comments